CHECKMATE-9X8

NCT03414983 📎

Regimen

Experimental
Nivolumab + mFOLFOX6 + bevacizumab
Control
Placebo + mFOLFOX6 + bevacizumab

Population

Unselected (predominantly MSS/pMMR) metastatic CRC, 1L, previously untreated.

Key finding

1L mCRC (predominantly MSS, unselected): phase 2 results: mPFS nivolumab arm 9.4 vs control 7.7 mo (HR 0.81, 95% CI 0.57-1.14, p=0.23, NS); mOS 25.7 vs 22.8 mo (HR 0.83, NS); ORR 59% vs 54%; primary PFS endpoint not met in phase 2; phase 3 continuing

Source: PMID 38485190

Timeline